Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efectos de un Antagonista/Agonista Inverso Del Receptor CB1 (Rimonabant) Sobre la Capacidad Para la deambulación en Lesionados Medulares Incompletos

NCT05622994 is registered in ClinicalTrials.gov with Hospital Nacional de Parapléjicos de Toledo as lead sponsor.

NCT NCT05622994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05622994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efectos de un Antagonista/Agonista Inverso Del Receptor CB1 (Rimonabant) Sobre la Capacidad Para la deambulación en Lesionados Medulares Incompletos
Lead sponsor
Hospital Nacional de Parapléjicos de Toledo
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2022
Completion date
November 30, 2023
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

spinal cord injuries